NCT00375518View on ClinicalTrials.gov

Study of Atorvastatin Versus Placebo to Reduce Cardiopulmonary Complications After Thoracic Surgery

NACompletedINTERVENTIONAL
Enrollment

162

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Thoracic Surgery
Interventions
DRUG

Atorvastatin

Atorvastatin 40 mg once a day beginning 7 days before the operation. Surgical procedures will be as planned and unaffected by this study. Starting from the day after surgery, patients will be given their study drug for an additional 7 days.

DRUG

Placebo

Placebo given beginning 7 days before the operation. Starting from the day after surgery, patients will be given their study drug for an additional 7 days.

Trial Locations (1)

10021

Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00375518 - Study of Atorvastatin Versus Placebo to Reduce Cardiopulmonary Complications After Thoracic Surgery | Biotech Hunter | Biotech Hunter